Compare Summit Therapeutics Inc (SMMT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tyson Foods, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Tyson Foods, Inc. trades at $53.35 (market cap $18.41B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Tyson Foods, Inc. for 76 Days on average.
| SMMT | TSN | |
|---|---|---|
Market Cap | $13.71B | $18.41B |
Volume | 6,173,057 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $26.38 | $68.75 |
52-Week Low | $12.43 | $50.47 |
Typical Hold Time | 16 Days | 76 Days |
Enterprise Value | $13.04B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Tyson Foods (TSN) trades at $52.70, up 1.93% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth remains modest at 1.5%-2.0% for 2026. Analysts maintain a Buy consensus with $65.40 target, but recent news highlights investigations into guidance revisions and beef segment challenges.
Outlook remains cautious with upside potential from execution improvements, but risks include beef segment losses, margin pressure, and ongoing securities investigations. The stock offers value with low P/S of 0.33 and consistent dividends, but requires monitoring of operational turnaround and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
